Select a medication above to begin.
Exdensur (depemokimab-ulaa)
depemokimab
Adult Dosing .
Dosage forms: INJ (pen): 100 mg per injection; INJ (pre-filled syringe): 100 mg per mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = depemokimab-ulaa
severe eosinophilic asthma, maintenance tx
- [100 mg SC q6mo]
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (pen): 100 mg per injection; INJ (pre-filled syringe): 100 mg per mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = depemokimab-ulaa
severe eosinophilic asthma, maintenance tx
- [12 yo and older]
- Dose: 100 mg SC q6mo
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- status asthmaticus
- asthma, acute
- bronchospasm, acute
- helminth infection
Drug Interactions .
Overview
depemokimab
IL-5 antagonist
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- hypersensitivity reaction
- anaphylaxis
- helminth infection risk
Common Reactions
- URI
- allergic rhinitis
- influenza
- arthralgia
- pharyngitis
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data and no animal data available, though likely to cross placenta based on human data w/ other monoclonal antibodies
Pregnancy Reporting
report pregnancy to GlaxoSmithKline at 1-888-825-5249
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for depemokimab: catabolism; CYP450: unknown
Excretion: for depemokimab: unknown; Half-life: 48 days
Subclass: Interleukin-5 (IL-5) Antagonists
Mechanism of Action
for depemokimab: exact mechanism of action unknown; binds to and interferes with interleukin-5 cytokine, reducing eosinophil production and survival (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.